BARCELONA, Spain--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat refractory sarcoma patients were presented by Rashmi Chugh, MD, Principal Investigator from the University of Michigan at the 14th Annual European Cancer Conference (ECCO) meeting being held in Barcelona, Spain. The trial has now enrolled 51 patients with soft tissue sarcoma or osteosarcoma and the reported interim dataset included the first 31 evaluable patients. These patients were refractory to treatment, having undergone a median of four prior regimens. Key findings for these 31 evaluable patients at the time of analysis include:
